The monitoring of biomarkers is essential for patients with inflammatory diseases. However, today’s LFA PoC products do not achieve the analytical sensitivity requirements, especially for some biomarkers. The goal of CentrImA is to combine the advantages of LFAs (quick, cost-efficient and easy to handle) with the strengths of the LabDisk (control of volume flow, precise sample volume, integration of sample preparations and the ability to run several tests in parallel). This seeks to improve on the quantification of the results, the sensitivity, the dynamic range and the possibility for multiplexing. Furthermore is this system a promising candidate for other areas of application e.g. in the oncology or cardiology.